Clinical Trial Update: Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial [Phase 3]

View source ↗

Summary

Phase 3 trial of S-1 for metastatic diffuse gastric cancer including carcinoma of the gastroesophageal junction was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of the Gastroesophageal Junction
• Diffuse Gastric Cancer

Drugs mentioned

• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction | Phase 3 | Status: TERMINATED | Results posted: 2022-05-17